Motif Neurotech is developing minimally invasive brain-computer interfaces that aim to bridge the gap between non-invasive EEG and fully invasive cortical implants. The company's technology uses a novel approach combining small, wireless implants with external processing units to achieve high-fidelity neural recording with reduced surgical risk. Founded with the goal of making BCI technology more accessible and safer, Motif represents an important advancement in the BCI field.
The company's technology targets the middle ground in the BCI invasiveness spectrum—offering signal quality approaching invasive systems while maintaining the safety profile of minimally invasive procedures. This approach makes BCI technology potentially available to a broader patient population, including those who may not be candidates for fully invasive systems.
The core technology platform includes several key innovations:
| Parameter |
Specification |
| Size |
Less than 1cm in diameter |
| Implant Location |
Epidural or subdural placement |
| Recording |
Local field potentials (LFP) |
| Wireless |
RF communication |
| Battery |
Rechargeable or energy harvesting |
| Channels |
Multiple electrode contacts |
| Surgery |
Minimally invasive procedure |
Motif's design prioritizes:
- Minimal invasiveness: Small device, brief procedure
- Reversibility: Can be removed if needed
- Safety: Reduced risk compared to open surgery
- Quality: High-fidelity neural signals
- Accessibility: Broader patient eligibility
Advanced algorithms enable effective neural decoding:
- Machine Learning Decoding: Real-time neural signal interpretation
- Motor Intention Detection: Movement planning signals identified
- Adaptive Algorithms: Self-tuning to individual neural patterns
- Low Latency: Responsive system for real-time control
Primary application focus with significant potential:
- Motor intention decoding: Controlling prosthetics and computers
- Closed-loop rehabilitation: Real-time feedback during therapy
- Cortical plasticity enhancement: Promoting brain reorganization
- Functional recovery: Restoring lost motor abilities
For PD patients, offering continuous monitoring and intervention:
- Movement state monitoring: Continuous tracking of motor states
- Adaptive stimulation integration: Working with existing DBS systems
- Tremor prediction: Preemptive intervention before tremor onset
- Dyskinesia management: Detecting and addressing involuntary movements
Monitoring and intervention applications:
- Seizure prediction: Neural pattern analysis for early warning
- Responsive neurostimulation: On-demand intervention for drug-resistant cases
- Long-term monitoring: Extended epilepsy monitoring without medications
- Pre-surgical mapping: Identifying seizure foci
Emerging applications for cognitive decline:
- Memory circuit monitoring: Tracking hippocampal activity
- Cognitive state assessment: Neural biomarkers of cognitive function
- Targeted neuromodulation: Memory enhancement approaches
- Disease progression tracking: Monitoring decline over time
Motif Neurotech's approach offers several distinct advantages:
- Reduced Surgical Risk: Brief outpatient procedure vs. major open-brain surgery
- Quick Recovery: Patients typically recover within days
- Reversibility: Device can be removed if desired
- Scalability: Designed for broad deployment
- Lower cost: Reduced surgical expenses
- High Fidelity: LFP signals provide rich neural information
- Stability: Reduced signal degradation over time
- Spatial resolution: Better than surface EEG
- Frequency content: Access to multiple neural frequency bands
- Wireless operation: No transcutaneous wires
- Battery life: Extended operation between charges
- Maintenance: Minimal ongoing requirements
- Comfort: Well-tolerated by patients
| Feature |
Motif |
Neuralink |
Synchron |
Non-invasive EEG |
| Invasiveness |
Minimally |
Invasive |
Minimally |
None |
| Surgery Duration |
Brief outpatient |
Major |
Endovascular |
None |
| Signal Quality |
High |
Very High |
Moderate |
Low-Moderate |
| Recovery Time |
Days |
Weeks |
Days |
None |
| Reversible |
Yes |
No |
Yes |
Yes |
| FDA Status |
Investigational |
Investigational |
Investigational |
Approved |
Motif aims to serve patients who:
- Are not candidates for fully invasive BCI
- Require higher signal quality than EEG provides
- Prefer reversible, removable options
- Need accessible, scalable solutions
Motif collaborates with leading institutions:
- Major research universities: Academic partnerships
- Medical device companies: Commercialization support
- Neurology centers: Clinical validation
- Rehabilitation centers: Therapy development
Animal studies demonstrate:
- Safe implantation procedures
- Stable long-term recording
- Effective neural decoding
- Biocompatibility of materials
Initial clinical data show:
- Safe implantation in human patients
- High-quality neural signals
- Successful motor intention decoding
- Acceptable safety profile
Clinical trials are evaluating:
- Stroke rehabilitation efficacy
- Parkinson's disease applications
- Long-term safety and performance
- Comparison with standard therapies
Future directions include:
- Larger channel count: More electrodes for improved resolution
- Enhanced durability: Improved materials for chronic implantation
- Fully implantable: No external components
- Closed-loop capabilities: Integrated stimulation
- Broader applications: Additional neurological conditions
- Combination therapies: Integrated with other treatments
- Personalized medicine: Individualized approaches
- Home use: Enabling remote therapy
- Regulatory approval: FDA clearance pathway
- Manufacturing scale: Production capabilities
- Clinical adoption: Healthcare system integration
- Patient access: Insurance coverage development
Motif is pursuing regulatory approval:
- FDA designations: Breakthrough device consideration
- Clinical trials: Phased trial approach
- Regulatory engagement: Ongoing agency communication
- Quality systems: Manufacturing quality standards